Could ozempic protect hearts in type 1 diabetes? new trial aims to find out

NCT ID NCT05819138

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether semaglutide, a drug already used for type 2 diabetes and weight loss, can improve heart and kidney function in adults with type 1 diabetes. The study will measure artery stiffness, insulin sensitivity, and kidney blood flow in 60 participants over time. Semaglutide is not FDA-approved for this use, so the results will help determine if it could become a new treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Ozempic)
What this could lead to: If it works, this could point toward a new way to protect heart and kidney health in people with type 1 diabetes.
What could go wrong: This is a small, early-phase trial in type 1 diabetes, and semaglutide is not yet approved for this use. It may not show the same benefits seen in type 2 diabetes, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

University of Colorado Anschutz Medical Campus
RECRUITING

Aurora, Colorado, 80045, United States
University of Washington Medicine Diabetes Institute (UWMDI)
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.